Compumedics’ MEG Growth Hinges on China Expansion Amid Global Market Challenges
Compumedics has landed a $4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, pushing total MEG sales in China to $25 million and reinforcing its leadership in the Asian neuro-imaging market.
- New $4.9 million MEG order from Beijing Normal University
- Total MEG contracted revenues reach approximately $25 million
- Three MEG systems scheduled to ship in FY26, one in FY27
- Technological edge with Orion LifeSpan MEG’s dual-helmet and helium recycling
- Ongoing efforts to re-enter North American market in 2026
Compumedics Expands MEG Footprint in China
Compumedics Limited (ASX – CMP) has announced a significant new order for its Orion LifeSpan™ magnetoencephalography (MEG) system, securing a $4.9 million contract with Beijing Normal University (BJNU). This latest sale marks the fifth MEG order in China, bringing the total contracted revenue for these advanced neuro-imaging systems to around $25 million. The deal underscores Compumedics’ growing influence in the rapidly expanding Chinese brain research market.
Beijing Normal University, a prestigious institution ranked among the top 200 universities globally and renowned for its research excellence, selected Compumedics following a competitive technical review. The order will be fulfilled in FY27, with an initial deposit expected imminently and milestone payments aligned with shipment and installation.
Technological Leadership with Orion LifeSpan™ MEG
The Orion LifeSpan MEG system distinguishes itself with patented Double Relaxation Oscillation Superconducting Quantum Interference Devices (DROS SQUIDs), offering superior accuracy over conventional MEG sensors. Its unique dual-helmet design accommodates both adult and pediatric patients, enabling hyperscanning capabilities that allow simultaneous brain activity recording from multiple subjects. Additionally, the system features a virtual 100% helium recycling mechanism, allowing continuous 24/7 operation without the need for helium refills; a significant operational advantage.
Complementing the hardware, Compumedics’ CURRY neuroimaging software enhances data analysis, providing powerful tools for brain research. The company’s recent release of CURRY 9 further advances its analytical capabilities, reinforcing its competitive edge in the neuro-imaging sector.
Strategic Growth and Market Outlook
Compumedics is shipping three MEG systems in FY26, with the newly secured BJNU system slated for FY27. This growing order book provides a solid revenue foundation through FY27, while the company actively pursues additional opportunities across China, North America, and Europe. The announcement also highlights ongoing progress toward re-entering the North American market in 2026, signaling broader international ambitions.
Executive Chairman David Burton expressed pride in the latest order, noting the significance of penetrating China’s lucrative neurosciences market with innovative MEG technology. Meanwhile, Global Neuro-Imaging Business Director Gordon Haid emphasized the Orion LifeSpan’s unique features as key factors in securing the BJNU contract, reinforcing Compumedics’ leadership position in Asia.
With the involvement of internationally renowned MEG/EEG expert Professor Liu Yunzhe as chief expert of the BJNU MEG team, Compumedics is well positioned to deepen its collaboration with leading researchers and expand its footprint in the global neuro-imaging landscape.
Bottom Line?
Compumedics’ expanding MEG sales pipeline signals robust growth ahead, but execution on shipments and market expansion will be critical to sustaining momentum.
Questions in the middle?
- How will Compumedics’ margins evolve as MEG sales scale in China and beyond?
- What are the timelines and prospects for re-entering the North American MEG market?
- Can Compumedics maintain its technological edge amid increasing global competition?
